Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INFANT BACTERIAL THERAPEUTICS AB (PUBL)

(IBT B)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Infant Bacterial Therapeutics : Annual General Meeting of Infant Bacterial Therapeutics

05/05/2021 | 07:38am EDT

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2021, among other things, the following was resolved:

adoption of the annual report, that no dividend is given, discharge from liability granted to board members and the Chief Executive Officer, that the board shall consist of six members without deputies, that remuneration should be paid to the Chairman of the Board of SEK 250,000 and an additional remuneration for the work as Chairman of the Board of SEK 400,000 and to other members of the company not employed by SEK 125,000 each. For members of the Remuneration Committee, a fee of forty thousand 40,000 is proposed to the Chairman and twenty thousand SEK 20,000 to each of the other members of the Committee, that the audit fee be paid according to approved invoice, re-election of Margareta Hagman, Eva Iden, Anthon Jahreskog, Kristina Sjoblom Nygren, Robert Molander and Peter Rothschild as board members, re-election of Peter Rothschild as Chairman of the Board, re-election of the registered accounting firm Deloitte AB, on the nomination committee in accordance with the nomination committee's proposal, guidelines for remuneration to senior executives in accordance with the Board's proposal, and, The Board's proposal for a resolution regarding mandate for a new issuance of B shares, About Infant Bacterial Therapeutics AB, Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in Phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.

IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis ('NEC') and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.

Infant Bacterial Therapeutics AB ('IBT') is a public company domiciled in Stockholm. The company's class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).

Contact:

Staffan Stromberg

CEO

Daniel Mackey

CFO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 70 670 1226

E: info@ibtherapeutics.com

Website: www.ibtherapeutics.com

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
BIOGAIA AB (PUBL) 2.85% 469 Delayed Quote.-15.08%
INFANT BACTERIAL THERAPEUTICS AB (PUBL) 15.18% 85 Delayed Quote.-34.11%
All news about INFANT BACTERIAL THERAPEUTICS AB (PUBL)
08:05aINFANT BACTERIAL THERAPEUTICS : IBT - After safety review The Connection study is now agai..
AQ
09/22INFANT BACTERIAL THERAPEUTICS : After safety review The Connection study is now again open..
AQ
09/13INFANT BACTERIAL THERAPEUTICS : announces that a new patent is granted in Mexico
AQ
09/10INFANT BACTERIAL THERAPEUTICS : today announces that a new patent is granted in Mexico
AQ
09/10Infant Bacterial Therapeutics Announces the Mexican Patent Office Grants New Patent
CI
08/25INFANT BACTERIAL THERAPEUTICS : Recruitment of the smallest infants in the Connection stud..
AQ
08/25Infant Bacterial Therapeutics AB Announces Recruitment of the Smallest Infants in the C..
CI
08/16INFANT BACTERIAL THERAPEUTICS AB : (publ) Interim Management Statement, January 1 - June 3..
AQ
08/13INFANT BACTERIAL THERAPEUTICS AB : (publ) Interim Management Statement,áJanuary 1 – ..
AQ
08/13Infant Bacterial Therapeutics AB Announces Interim Management Statement for the Second ..
CI
More news
Financials
Sales 2020 - - -
Net income 2020 -72,0 M -8,34 M -8,34 M
Net cash 2020 423 M 49,0 M 49,0 M
P/E ratio 2020 -17,5x
Yield 2020 -
Capitalization 828 M 95,9 M 96,0 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 8
Free-Float 89,2%
Chart INFANT BACTERIAL THERAPEUTICS AB (PUBL)
Duration : Period :
Infant Bacterial Therapeutics AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INFANT BACTERIAL THERAPEUTICS AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Staffan Str÷mberg Chief Executive Officer
Marie-Louise Alamaa Chief Financial Officer
Peter Michael Rothschild Chairman
Eamonn Connolly Chief Scientific Officer
Jonas Rastad Chief Medical Officer